Skip to main content

Advertisement

Fig. 6 | Journal of Translational Medicine

Fig. 6

From: A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis

Fig. 6

L4.8 vaccination protects from Mtb. BCG primed mice were boosted after 21 days twice with L4.8 and control groups with L91 or lipidated hemagglutinin virus peptide (20 nmol) or with PBS at an interval of 2 weeks. After 90 days, mice were infected with Mtb. Ninety days later, bacterial burden in the lungs was enumerated by CFUs. Bar diagram represents CFUs per gram of a lung and b spleen tissue. c Histopathological section of lungs were stained with hematoxylin and eosin and examined at a magnification ×20/×100. The arrows indicate granulomas or tubercle. Experimental groups signify that mice inoculated with ‘Placebo’: PBS, BCG: BCG, LH: BCG priming and LH (hemagglutinin peptide) boosting, L91: BCG priming and L91 boosting, L4.8: BCG priming and L4.8 boosting. Results shown as bar diagram are mean ± SEM and pooled data from 2 independent experiments (n = 3 mice/group). *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.0005, ****p ≤ 0.0001

Back to article page